Pediatrix Medical Group, Inc. filings document the public-company disclosures of a Florida physician-services operator focused on obstetrics, maternal-fetal medicine, neonatology and pediatric subspecialty care. Recent Form 8-K reports furnish operating results, including net revenue, earnings measures, same-unit revenue drivers, reimbursement factors, patient volume trends and hospital-based practice activity.
Proxy and governance filings cover director elections, shareholder voting results, executive compensation, pay-versus-performance data and the Pediatrix Medical Group, Inc. Second Amended and Restated 2008 Incentive Compensation Plan. Other material-event reports address board appointments, Regulation FD disclosures and common-stock repurchase authorizations.
Newman Kurt Douglas reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director Kurt Douglas Newman received a grant of 7,196 shares of restricted common stock as an annual equity award. The award was granted at no cash cost to him under the company’s Amended and Restated 2008 Incentive Compensation Plan and will vest on May 7, 2027. After this grant, he directly holds 16,933 Pediatrix common shares.
Pediatrix Medical Group, Inc. reported results from its 2026 Annual Shareholders’ Meeting. Shareholders approved the Second Amended and Restated 2008 Incentive Compensation Plan, increasing the number of common shares available for equity awards by 8,000,000 shares.
All director nominees were elected to serve until the 2027 Annual Shareholders’ Meeting, with each receiving over 69 million votes in favor, except one nominee who received lower support but was still elected. Shareholders also ratified PricewaterhouseCoopers LLP as independent auditor for the 2026 fiscal year and approved, on an advisory basis, executive compensation for 2025.
The meeting had strong participation, with 77,330,139 of 83,072,104 shares outstanding represented, constituting a quorum. The amended incentive plan and governance proposals are detailed further in the company’s previously filed proxy statement and attached exhibit.
Pediatrix Medical Group reported stronger quarterly results. Net revenue for the three months ended March 31, 2026 rose to $476.2 million from $458.4 million, driven mainly by a 2.8% increase in same-unit revenue and contributions from recent acquisitions.
Net income increased to $29.6 million from $20.7 million, with diluted EPS up to $0.36 from $0.24 and operating margin improving to 8.7% from 7.0%. Adjusted EBITDA grew to $58.2 million from $49.2 million. The company ended the quarter with $205.8 million in cash, no borrowings on its $450.0 million revolver, and completed a $7.9 million maternal-fetal medicine acquisition while repurchasing about 1.0 million shares for $19.9 million.
Pediatrix Medical Group reported stronger first quarter 2026 results, with net revenue of $476.2 million for the three months ended March 31, 2026, up from $458.4 million a year earlier. Earnings were $0.36 per diluted share, and Adjusted EPS, which excludes items such as amortization, stock-based compensation and transformational and restructuring expenses, was $0.44.
Net income was $30 million and Adjusted EBITDA reached $58 million. Same-unit revenue grew 2.8 percent, driven mainly by a 4.4 percent increase in same-unit revenue from net reimbursement-related factors, reflecting better cash collections, higher hospital contract administrative fees, higher patient acuity and a slightly favorable payor mix. Same-unit patient volume declined by 1.6 percent.
As of March 31, 2026, Pediatrix reported cash and cash equivalents of $205.8 million, total debt of $590.8 million and total shareholders’ equity of $878.6 million.
Pediatrix Medical Group, Inc. is holding its 2026 Annual Shareholders’ Meeting as a virtual-only webcast on May 7, 2026, asking investors to elect nine directors, ratify PricewaterhouseCoopers LLP as auditor, approve 2025 executive pay on an advisory basis, and approve the Second Amended and Restated 2008 Incentive Compensation Plan.
Shareholders of record at the close of business on March 9, 2026, when 83,072,104 common shares were outstanding, are entitled to vote. The board recommends voting “FOR” all four main proposals and uses majority voting in uncontested director elections with a resignation policy for nominees receiving more “against” than “for” votes.
The proxy details Pediatrix’s governance structure, including combined Chair/CEO with a Lead Independent Director, fully independent key board committees, cybersecurity and sustainability oversight, and codes of conduct and insider trading policies. It also explains a largely performance-based pay program tied to Adjusted EBITDA, ROIC and strategic goals, with strong prior say‑on‑pay support and a formal sustainability program that included $2.6 million in 2025 charitable donations.
Pediatrix Medical Group EVP and General Counsel Mary Ann E. Moore reported equity transactions in company common stock. She acquired 39,925 shares on March 1, 2026 as a share award tied to performance conditions from a program established on March 1, 2023.
On the same date, 26,931 shares were withheld to satisfy tax obligations upon vesting of shares at a price of $19.85 per share. After these direct transactions, she held 149,236 shares directly. An additional 52,598 shares are held indirectly through a trust for which she and her spouse serve as trustees.
Pediatrix Medical Group, Inc. reported that its EVP, CFO and Treasurer, Kasandra H. Rossi, had 3,676 shares of common stock withheld on a Form 4 filing. These restricted shares were withheld at $19.85 per share to cover taxes due upon vesting, rather than being sold in the open market.
After this tax-withholding disposition, Rossi directly holds 73,300 shares of Pediatrix common stock. This type of transaction is a routine administrative step tied to equity compensation vesting.
Pediatrix Medical Group, Inc. (MD) provides neonatal, maternal-fetal and other pediatric physician services. At December 31, 2025, its network included approximately 2,295 affiliated physicians in 37 states. Net revenue was $1.914 billion for 2025, compared with $2.013 billion in 2024; net income was $165.4 million, versus a net loss of $99.1 million. Operating cash flow was $271.1 million, compared with $206.6 million.
Pediatrix completed two acquisitions in 2025 for a total purchase price of $24.5 million, including $23.2 million paid in cash at closing and $1.3 million recorded as contingent consideration. It repurchased $86.7 million of common stock. After a related company was acquired in the third quarter, Pediatrix received $30 million in cash for an investment and recognized a $28.8 million gain.
Pediatrix Medical Group reported stronger profitability for the quarter and year ended December 31, 2025. For the fourth quarter, diluted EPS was $0.40, with Adjusted EPS of $0.50 on net revenue of $493.8 million, down slightly from $502.4 million a year earlier. Same-unit net revenue grew 4.0%, driven by a 6.7% increase from reimbursement-related factors, while same-unit patient service volumes declined 2.7%.
For full-year 2025, net income was $165.4 million versus a net loss of $99.1 million in 2024, translating to diluted EPS of $1.94 compared with a loss of $1.19. Adjusted EBITDA rose to $275.6 million from $224.0 million, and full-year Adjusted EPS increased to $2.04 from $1.51.
Liquidity and leverage also improved. Cash and cash equivalents increased to $375.2 million from $229.9 million, while total debt decreased to $597.3 million from $617.7 million. For 2026, the company projects Adjusted EBITDA between $280 million and $300 million.